Evidence map›Paper›PMID 26556047›Full record

ArticlePloS one2015

Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis.

Samuel A Shelburne, Nadim J Ajami, Marcus C Chibucos, Hannah C Beird, Jeffrey Tarrand, Jessica Galloway-Peña, Nathan Albert, Roy F Chemaly, Shashank S Ghantoji, Lisa Marsh and 10 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Whole-genome sequence ofMicrobiology resource announcements · 2024
    Article
  6. Mucormycosis: A Rare disease to Notifiable Disease.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Review
  7. The Impact of Dimitrios P. Kontoyiannis on Mucormycosis Research.Journal of fungi (Basel, Switzerland) · 2024
    Article
  8. Oral Mycobiota: A Narrative Review.Dentistry journal · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Samuel A ShelburneDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Nadim J AjamiThe Alkek Center for Metagenomics and Microbiome Research and the Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, United States of America.
Marcus C ChibucosDepartment of Microbiology & Immunology and Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Hannah C BeirdDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Jeffrey TarrandDepartment of Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Jessica Galloway-PeñaDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Nathan AlbertDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Roy F ChemalyDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Shashank S GhantojiDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Lisa MarshDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Naveen PemmarajuDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Michael AndreeffDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Jennifer A WargoDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Katayoun RezvaniDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Amin AlousiDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Vincent M BrunoThe Alkek Center for Metagenomics and Microbiome Research and the Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, United States of America.
Phillip A FutrealDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Joseph F PetrosinoThe Alkek Center for Metagenomics and Microbiome Research and the Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, United States of America.
Dimitrios P KontoyiannisDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USUniversity of Maryland, Baltimore · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RASKO, DAVID A · 2014 to 2023
$36.5M
Hematopoietic Progenitor Cells- Cord BloodR01CA061508 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REZVANI, KATY, SHPALL, ELIZABETH J · 1993 to 2020
$5.1M
Contribution of catabolite control protein A to group A streptococcal virulenceR01AI089891 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHELBURNE, SAMUEL A · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA061508NIAID NIH HHS HHSN272200900009CNIAID NIH HHS R01 AI089891NIAID NIH HHS R01AI089891NIAID NIH HHS U19 AI110820NIAID NIH HHS U19AI110820PHS HHS HHSN272200900009C
6 · The paper itself

Abstract

Disease can be conceptualized as the result of interactions between infecting microbe and holobiont, the combination of a host and its microbial communities. It is likely that genomic variation in the host, infecting microbe, and commensal microbiota are key determinants of infectious disease clinical outcomes. However, until recently, simultaneous, multiomic investigation of infecting microbe and holobiont components has rarely been explored. Herein, we characterized the infecting microbe, host, micro- and mycobiomes leading up to infection onset in a leukemia patient that developed invasive mucormycosis. We discovered that the patient was infected with a strain of the recently described Mucor velutinosus species which we determined was hypervirulent in a Drosophila challenge model and has a predisposition for skin dissemination. After completing the infecting M. velutinosus genome and genomes from four other Mucor species, comparative pathogenomics was performed and assisted in identifying 66 M. velutinosus-specific putatively secreted proteins, including multiple novel secreted aspartyl proteinases which may contribute to the unique clinical presentation of skin dissemination. Whole exome sequencing of the patient revealed multiple non-synonymous polymorphisms in genes critical to control of fungal proliferation, such as TLR6 and PTX3. Moreover, the patient had a non-synonymous polymorphism in the NOD2 gene and a missense mutation in FUT2, which have been linked to microbial dysbiosis and microbiome diversity maintenance during physiologic stress, respectively. In concert with host genetic polymorphism data, the micro- and mycobiome analyses revealed that the infection developed amid a dysbiotic microbiome with low α-diversity, dominated by staphylococci. Additionally, longitudinal mycobiome data showed that M. velutinosus DNA was detectable in oral samples preceding disease onset. Our genome-level study of the host-infecting microbe-commensal triad extends the concept of personalized genomic medicine to the holobiont-infecting microbe interface thereby offering novel opportunities for using synergistic genetic methods to increase understanding of infectious diseases pathogenesis and clinical outcomes.

Indexed as

Genome, FungalAntifungal AgentsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy-Induced Febrile NeutropeniaFungal ProteinsFungemiaGastrointestinal MicrobiomeHost-Pathogen InteractionsHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMucorMucormycosisNeoplasm ProteinsOnychomycosisAntifungal AgentsFungal ProteinsNeoplasm Proteins

Identifiers

PMID26556047
PMCPMC4640583
OpenAlexW2213879604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.